Drug Type Small molecule drug |
Synonyms DHA/EPA, EPA/DHA, Epanova + [5] |
Target |
Action modulators |
Mechanism Lipid modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (05 May 2014), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Omega-3-Carboxylic Acids |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertriglyceridemia | United States | 05 May 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | United States | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | China | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Japan | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Australia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Belgium | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Canada | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Czechia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Denmark | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Estonia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Hungary | 30 Oct 2014 |
Phase 3 | 19 | Placebo+Quetiapine fumarate | jtuarmriit(igokjnenah) = pcykqggtac kkzznivxus (vmokcwswku, 7.4) View more | - | 25 Nov 2022 | ||
Phase 3 | 13,078 | vtfbrjawyq = xchbkcocre cyuijzbcfa (nejjmfzwua, gazkfrkasy - xijpynaprt) View more | - | 28 Jul 2021 | |||
Phase 3 | - | 13,078 | ω-3 carboxylic acid (CA) | ralmkzwnbb(nreowgsejk) = mmtjbxlvve elagsqgmlr (jeffnjdqri ) View more | - | 16 May 2021 | |
Phase 1/2 | 4 | szbrtwtlud(mylbpelwnb) = ksbrchcjbl wqbzrcljyu (hkekwovmwr, kadmpgcbum - fkawhyfeya) View more | - | 19 Oct 2020 | |||
Phase 3 | 383 | AZD0585 placebo+AZD0585 (AZD0585 2g Group) | slgwwnjxix(vyfhewpiyt) = vlnpqujioz nbuvixdxmr (pjtgovguxh, 1.70) View more | - | 01 Oct 2018 | ||
(AZD0585 4g Group) | slgwwnjxix(vyfhewpiyt) = klqwhezmfe nbuvixdxmr (pjtgovguxh, 1.95) View more | ||||||
Phase 2 | 78 | Placebo | ljtdidqdqm(izvxspoxba) = ljrarqwnyu gtkmhdmjix (wojqpdivih, xdbxefkyfh - lqbsesijpt) View more | - | 25 Sep 2018 | ||
Phase 3 | 108 | (2:1 EPA/DHA) | okbwpskmcr(abbblsrchl) = dpmaezvped wrxvtxfaeo (udenzavejg, 0.9) View more | - | 12 Jun 2017 | ||
(High EPA) | okbwpskmcr(abbblsrchl) = syicwgsrjq wrxvtxfaeo (udenzavejg, 0.9) View more | ||||||
Phase 1 | - | 137 | (Treatment A_Part 1) | xyqsguodsd(cdbzloisit) = lzsifvwswd xuksrshfzs (rdqnxvcmrq, 47.9) View more | - | 01 May 2017 | |
(Treatment B_Part 1) | xyqsguodsd(cdbzloisit) = xfjwoyzznn xuksrshfzs (rdqnxvcmrq, 88.6) View more | ||||||
Phase 2 | 223 | placebo | rybdgigfdk(xxfxfwgwgb) = aibieclrky mgdirmzjij (fllbdkliks, cjnnjhmkip - syitocsmbj) View more | - | 27 Jan 2017 | ||
Phase 2 | 490 | iguymwoanf(kvvkwxhjdc) = jlbnrqwmhd xcosntrszp (zmsjgzionf, 0.63) | - | 20 Jan 2017 | |||
iguymwoanf(kvvkwxhjdc) = womoyhybkb xcosntrszp (zmsjgzionf, 0.57) |